Profound Medical Announces Positive CAPTAIN Trial Results

Profound Medical ( (TSE:PRN) ) just unveiled an announcement.

On April 29, 2025, Profound Medical Corp. announced positive initial perioperative data from the CAPTAIN trial, presented at the American Urological Association’s Annual Meeting. The trial compared the TULSA procedure with robotic radical prostatectomy (RP) in men with intermediate-risk prostate cancer, showing TULSA’s statistically significant improvements in post-operative experience, including no blood loss, reduced pain, and faster recovery. These results highlight TULSA’s potential to become a mainstream treatment, offering superior patient experience and satisfaction, which could impact insurance coverage policies and patient demand.

Spark’s Take on TSE:PRN Stock

According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.

Profound Medical’s stock reflects mixed performance; strong revenue growth and strategic initiatives are offset by ongoing operational inefficiencies and financial challenges. Technical indicators suggest caution, and the valuation is hindered by sustained losses. Optimistic growth prospects from the earnings call offer potential, but strategic improvements are crucial for future success.

To see Spark’s full report on TSE:PRN stock, click here.

More about Profound Medical

Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. The company is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control, aimed at treating the full spectrum of prostate disease. Profound is also commercializing Sonalleve®, a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

YTD Price Performance: -42.61%

Average Trading Volume: 6,252

Technical Sentiment Signal: Buy

Current Market Cap: C$197.1M

For a thorough assessment of PRN stock, go to TipRanks’ Stock Analysis page.